demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderate
COVID-19 mild to moderate
antiviral and associated therapy
azithromycin COALITION I Covid-19 Brazil ... Rashad A ...
azvudine Ren
bromhexine Li T
chloroquine and derivatives
chloroquine NCT04342650
hydroxychloroquine Zhaowei Chen Kamran Coalition Covid-19 Brazil I ... NCT04333654 FACCT Trial HC-nCoV ... Dubee
Ensitrelvir (XOCOVA) Mukae - Phase 2a
favipiravir NCT04542694 Holubar M IRCT20151227025726N14 // U07 Ruzhentsova T FACCT Trial Dabbous HM Shinkai Udwadia AVIFAVIR Solaymani-Dodaran Shenoy S
favipiravir plus interferon Khamis
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine Coalition Covid-19 Brazil I ...
ivermectin Bukhari Kirti Abd-Elsalam Babalola Krolewiecki RIVET-COV ... Ahmed Chachar I-TECH ... Chaccour Mayer Shahbaznejad
ivermectin plus doxycycline NCT04523831 ...
lopinavir/ritonavir ELACOI ...
lopinavir/ritonavir, ribavirin and interferon beta-1b Hung et al.
nitazoxanide Fontanesi Rocco Silva
remdesivir GS-US-540-5774, 5 days GS-US-540-5773 ... GS-US-540-5774, 10 days
sofosbuvir and ledipasvir Nourian A
umifenovir (arbidol) Yethindra ELACOI ...

9 studies excluded by filtering options 1

6064 Glorial F, 2020 1100not a RCTrisk of bias not avaialble
6381 Espitia-Hernandez, 2020 1310not a RCTrisk of bias not avaialble
6381 Espitia-Hernandez, 2020 1310not a RCTrisk of bias not avaialble
6382 Khan, 2020 0130selection pending
6383 Soto-Becerra, 2020 0122selection pending
6384 Spoorthi, 2020 1310not a RCTrisk of bias not avaialble
6384 Spoorthi, 2020 1310not a RCTrisk of bias not avaialble
6625 Nasir, 2020 2310excludednot a RCTrisk of bias not avaialble
7995 Hazan, 2021 2320excludednot a RCTrisk of bias not avaialble